Current treatment of advanced prostate cancer.
Publication/Presentation Date
1-1-1997
Abstract
Metastatic prostate cancer has been traditionally treated with androgen ablation using surgical orchiectomy or estrogens. The development of long lasting LHRH analogues has replaced these standard treatments in most patients with advanced prostate cancer. Several nonsteroidal antiandrogens are now available that may be used in combination therapy with LHRH analogues. This approach has been demonstrated in several large trials to improve the control of the disease. In spite of these advances, most men will eventually develop hormone resistance. New strategies being investigated include intermittent androgen ablation and combining initial hormonal therapy with chemotherapeutic agents. The management of hormone refractory disease remains a major clinical problem, with few standard chemotherapy agents demonstrating activity. This article reviews the principles of the current management of advanced prostate cancer and introduces some of the newer strategies under investigation.
Volume
3
Issue
1
First Page
16
Last Page
24
ISSN
1079-3259
Published In/Presented At
Ismail, M., & Gomella, L. G. (1997). Current treatment of advanced prostate cancer. Techniques in urology, 3(1), 16–24.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
9170220
Department(s)
Administration and Leadership
Document Type
Article